Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials

Journal of Thrombosis and Thrombolysis

Volumn 38, Issue 2, 2014, Pages 150-159

  Amin, Alpesh ^a   Deitelzweig, Steve ^b   Jing, Yonghua ^c   Makenbaeva, Dinara ^c   Wiederkehr, Daniel ^d   Lin, Jay ^e   Graham, John ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OCHSNER CLINIC FOUNDATION   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d PFIZER INC   (United States)

^e Novosys Health   (United States)

Author keywords

Atrial fibrillation; Oral anticoagulants; Stroke; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; COST CONTROL; DOSE TIME EFFECT RELATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HUMAN; NONVALVULAR ATRIAL FIBRILLATION; PRIORITY JOURNAL; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); COST; ECONOMICS; FEMALE; MALE;

ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; COSTS AND COST ANALYSIS; FEMALE; HEMORRHAGE; HUMANS; MALE; STROKE; WARFARIN;

EID: 84904764487     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-1048-z     Document Type: Article

References (41)

1. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS (2006) Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980-2000, and implications on the projections for future prevalence. Circulation 114:119-125 (Pubitemid 44420743)
2. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 285:2370-2375 (Pubitemid 32424106)
3. Miniño BAM, Murphy SL, Jiaquan X, Kochanek KD (2011) National vital statistics reports deaths: final data for 2008 59:1-157
4. Naccarelli GV, Varker H, Lin J, Schulman KL (2009) Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 104:1534-1539
5. Kim MH, Lin J, Hussein M, Kreilick C, Battleman D (2009) Cost of atrial fibrillation in United States managed care organizations. Adv Ther 26:847-857
6. Hart RG, Pearce LA, Aguilar MI (2007) Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146:857-867 (Pubitemid 351650486)
7. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, Lip GY, Manning WJ, American College of Chest Physicians (2008) Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133:546S-592S (Pubitemid 351892972)
8. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Kay GN, Le Huezey JY, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS (2011) 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/ AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 57:e101-e198
9. Atrial Fibrillation Investigators (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154:1449-1457
10. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, American College of Chest Physicians (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133:160S-198S (Pubitemid 351892967)
11. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367:1903-1912
12. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators (1998) Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. JAMA 279:1273-1277
13. Miura T, Nishinaka T, Terada T, Yonezawa K (2009) Relationship between aging and dosage of warfarin: the current status of warfarin anticoagulant therapy for Japanese outpatients in a Department of Cardiovascular Medicine. J Cardiol 53:355-360
14. Baker WL, Cios DA, Sander SD, Coleman CI (2009) Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 15:244-252
15. Birman-Deych E, Radford MJ, Nilasena DS, Gage BF (2006) Use and effectiveness of warfarin in medicare beneficiaries with atrial fibrillation. Stroke 37:1070-1074
16. Caro JJ (2004) An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care 10:S451-S458
17. Chiquette E, Amato MG, Bussey HI (1998) Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 158:1641-1647 (Pubitemid 28371187)
18. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139-1151
19. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez- Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees Investigators (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981-992
20. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKETAF Investigators (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883-891
21. Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J (2012) Medical cost reductions associated with the usage of novel oral anticoagulants versus warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF and ARISTOTLE trials. J Med Econ 15:776-785
22. Boehringer Ingelheim Pharmaceuticals Inc. FDA draft briefing document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC). NDA 22-512: PRADAXA® (dabigatran etexilate) tablets
23. Janssen Pharmaceuticals Inc (2011) FDA draft briefing document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC). NDA 202439: XARELTO® (rivaroxaban) tablets
24. Bureau of Labor Statistics US Department of Labor. Consumer Price Index December 2010. USDL-11-0018 2011. http://www.bls.gov/news.release/archives/cpi- 01142011.pdf. Accessed 17 May 2013
25. Mercaldi CJ, Ciarametaro M, Hahn B, Chalissery G, Reynolds MW, Sander SD, Samsa GP, Matchar DB (2011) Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation. Stroke 42:112-118
26. Sorensen SV, Kansal AR, Connolly S, Peng S, Linnehan J, Bradley-Kennedy C, Plumb JM (2011) Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Throm Haemost 105:908-919
27. Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M (2011) Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med 171:218-225
28. Spyropoulos AC, Lin J (2007) Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 13:475-486 (Pubitemid 350193368)
29. Center for Medicare and Medicaid Services. Medicare fee schedule, payment and reimbursement benefit guideline, CPT code billing: medicare fee schedule for office visit CPT codes-2011, CPT code 99213, 99214, 99203. http://www.medicarepaymentan dreimbursement.com/p/medicare-fee-schedule-for- office-visit.html. Accessed 17 May 2013
30. Wallentin L, Lopes RD, Hanna M et al (2013) Efficacy and safety of apixaban compared with warfarin at different levels of predicted INR control for stroke prevention in atrial fibrillation. Circulation 127:2166-2176
31. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S, ACTIVEW Investigators (2008) Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 118:2029-2037
32. Gottlieb LK, Salem-Schatz S (1994) Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 154:1945-1953 (Pubitemid 24276379)
33. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ, RE-LY investigators (2010) Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376:975-983
34. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE (2011) A new risk scheme to predict warfarin-associated hemorrhage: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. J Am Coll Cardiol 58:395-401
35. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115:2689-2696 (Pubitemid 46842784)
36. Ansell JE, Hughes R (1996) Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring, and patient self-management. Am Heart J 132:1095-1100 (Pubitemid 26372785)
37. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW (2007) Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 167:239-245
38. Veeger NJ, Piersma-Wichers M, Tijssen JG, Hillege HL, van der Meer J (2005) Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. A retrospective study of 2300 consecutive patients with venous thromboembolism. Br J Haematol 128:513-519 (Pubitemid 40283170)
39. Analy$ource Online (2013) First Databank Inc., South San Francisco
40. Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC (2013) Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 44:1676-1681
41. The Henry J Kaiser Family Foundation. US health care costs: issue modules, background brief. http://www.kaiseredu.org/Issue-Modules/US-Health- Care-Costs/Background-Brief.aspx. Accessed 17 May 2013